Lower clinical trial costs - The company said the decrease in R&D expense was mainly due to lower clinical trial costs as patients moved from active dosing to follow-up in the Phase 2 ELI-002 7P study.
Complete responses observed - The company reported multiple complete responses following ELI-002 7P treatment and checkpoint inhibition in metastatic pancreatic cancer.
Subgroup analysis continues - Elicio continues to evaluate pre-specified subgroups from the Phase 2 AMPLIFY-7P trial to refine its Phase 3 development strategy for ELI-002 7P.
Key financial details
Metric
Actual
Q2 Net Loss
$8.22 million
Q2 Income from Operations
-$10.43 million
Q2 Loss Per Basic Share
$0.43
Q2 Operating Expenses
$10.43 million
Q2 results and cash position
US biotech firm's Q2 net loss narrowed year over year as R&D expenses declined.
ELTX•
